MV Electrosystems

MV Electrosystems has established its presence in the diagnostic healthcare industry since 2013, building its brand over 12 years through dedicated R&D and quality assurance. The company specializes in the manufacturing and distribution of a diverse range of reagents, including Clinical Chemistry, Haematology, Immunodiagnostics, and Molecular Diagnostics.

During the Covid-19 pandemic, the company strategically diversified its portfolio by developing a range of Covid testing kits, such as RT-PCR and RNA Extraction Kits, through technical collaborations with third-party institutes. This adaptability underscores its research-driven approach to healthcare solutions.

The business model leverages both indigenous manufacturing and international technical collaborations to ensure that equipment and devices adhere to strict global quality certifications. This dual approach allows them to offer a comprehensive suite of IVD products to a wide network of diagnostic service providers and hospitals.

Operationally, the company maintains a significant human resource base with 362 permanent employees and 223 contract employees as of March 31, 2026. A specialized team of 19 personnel is dedicated to R&D laboratories, representing approximately 5.25% of its permanent workforce, ensuring continuous product innovation.

The IPO consists of a maiden book-building issue of 6,253,200 equity shares with a price band of ₹326 to ₹343 per share. The total issue aims to mobilize ₹214.48 crore, with the shares slated for listing on the NSE SME Emerge platform. The minimum application lot is 800 shares.

Proceeds from the fresh issue are earmarked for strategic growth and liability management. Specifically, ₹93.50 crore will be utilized for working capital requirements, while ₹90.00 crore is allocated for the repayment or prepayment of certain borrowings, with the remaining funds for general corporate purposes.

Financial performance shows steady top-line growth, with revenues increasing from ₹184.81 crore in FY23 to ₹322.58 crore in FY25. However, the bottom line has been inconsistent; PAT dropped to ₹28.13 crore in FY25 following accounting adjustments, though it surged to ₹38.69 crore in the first 9 months of FY26.

Valuation remains a point of contention as there are no direct listed peers for comparison. Based on FY26's elevated earnings, the P/E is approximately 15.51, but based on FY25, it rises to 28.44. The company is seeking a market capitalization of ₹800.16 crore at the upper band.

Key risks include high overall borrowings of ₹242.57 crore and contingent liabilities amounting to ₹61.64 crore as of December 2025. Investors should also note the sustainability of the recent 'bumper' profits reported in the pre-IPO period.

Overall, while the strong subscription numbers indicate high market interest, the lack of peer benchmarks and the debt levels suggest a cautious approach. The issue may be attractive for medium to long-term investors who believe in the IVD sector's growth.